Table 1 Baseline characteristics in older adults with newly diagnosed high-risk/secondary AML [7]
Characteristic | CPX-351 (n = 153) | 7 + 3 (n = 156) |
|---|---|---|
Demographic characteristics | ||
Age | ||
Mean (SD), y | 67.8 (4.2) | 67.7 (4.1) |
60 to 69 y, n (%) | 96 (63) | 102 (65) |
70 to 75 y, n (%) | 57 (37) | 54 (35) |
Male, n (%) | 94 (61) | 96 (62) |
ECOG performance status, n (%) | ||
0 | 37 (24) | 45 (29) |
1 | 101 (66) | 89 (57) |
2 | 15 (10) | 22 (14) |
Clinical characteristics | ||
AML subtype, n (%) | ||
Therapy-related AML | 30 (20) | 33 (21) |
AML with antecedent MDS | ||
With prior HMAs | 50 (33) | 55 (35) |
Without prior HMAs | 21 (14) | 19 (12) |
AML with antecedent CMML | 11 (7) | 12 (8) |
de novo AML with MDS karyotype | 41 (27) | 37 (24) |
Prior HMA therapy, n (%)a | 62 (41) | 71 (46) |
Cytogenetic risk by NCCN, n (%) | 143 | 146 |
Favorable | 7 (5) | 5 (3) |
Intermediate | 64 (45) | 58 (40) |
Unfavorable | 72 (50) | 83 (57) |
Median (range) bone marrow blasts, % | 35 (5, 93) | 35 (3, 97) |
WBC count < 20,000/µL, n (%)b | 131 (86) | 131 (85) |
Number of induction cycles received, n (%)c 1 2 | 153 105 (69) 48 (31) | 151 100 (66) 51 (34) |
Number of consolidation cycles received, n (%)c 1 2 | 153 26 (17) 23 (15) | 151 20 (13) 12 (8) |